GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
University of Maryland, Baltimore
Eastern Cooperative Oncology Group
Spanish Breast Cancer Research Group
University of Chicago
Allarity Therapeutics
Penn State University
Dana-Farber Cancer Institute
Baylor College of Medicine
M.D. Anderson Cancer Center
Stanford University
University of Virginia
Dana-Farber Cancer Institute
Takeda
Fundacio Clinic Barcelona
Stanford University
Ottawa Hospital Research Institute
Sanofi
Bolt Biotherapeutics, Inc.
Pfizer
Taiho Oncology, Inc.
University of Southern California
Tempus AI
Incyte Corporation
Institut Bergonié
Zenith Epigenetics
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
University of California, San Francisco
Georgetown University
Sanofi
Sanofi
Sanofi
SBI ALApharma Canada, Inc.
University of Alabama at Birmingham
Alaunos Therapeutics
Alaunos Therapeutics
Eli Lilly and Company
University of Texas Southwestern Medical Center
Hoffmann-La Roche
Washington University School of Medicine
Eli Lilly and Company
Hutchmed
Daiichi Sankyo
M.D. Anderson Cancer Center
NRG Oncology
SOLTI Breast Cancer Research Group
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Pfizer